
NCTN Pediatric Solid Tumor (other than Brain/CNS) Trials (Open as of 11/15/2025)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.



NCTN Pediatric Solid Tumor (other than Brain/CNS) Trials (Open as of 11/15/2025)

Protocol Number	Phase	Protocol Title
		Randomized Phase 2/3 Trial of Vincristine-Irinotecan-Regorafenib in Combination with
		Vincristine-Doxorubicin-Cyclophosphamide (VDC) and Ifosfamide-Etoposide (IE) in Patients with
AEWS2431	11/111	Newly Diagnosed Metastatic Ewing Sarcoma
		A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs.
AGCT1531	Ш	Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
		A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients
AGCT1532	Ш	with Intermediate and Poor-Risk Metastatic Germ Cell Tumors
		A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added
ANBL1531	Ш	to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL)
		A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with
ANBL2131	Ш	Newly Diagnosed High-Risk Neuroblastoma
		A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of
AOST2031	Ш	Pulmonary Metastases in Patients with Osteosarcoma
		A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in
AOST2032	11/111	Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
		A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in
ARAR2221	П	Newly Diagnosed Nasopharyngeal Carcinoma (NPC)
ARAR2331	Ш	Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB)
		Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed
AREN1921	П	Favorable Histology Wilms Tumors (FHWT)
AREN2231	Ш	Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)
ARET2121	II	Intravitreal Melphalan for Intraocular Retinoblastoma
		A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-Risk and Low-Risk
ARST2032	Ш	Fusion Negative Rhabdomyosarcoma